Monte Rosa Therapeutic (GLUE) Jefferies Global Healthcare Conference 2025 summary

Platform overview and differentiation

• Molecular glue degraders enable targeting of proteins without accessible binding pockets, expanding the range of druggable targets beyond what is possible with PROTACs.

• The pipeline includes programs in oncology, autoimmunity, and emerging areas like cardiovascular and metabolic diseases.

• Strategic focus is on high unmet need indications with undruggable targets, leveraging the platform's versatility.

GSPT1 (MRT-2359) program in oncology

• MRT-2359 targets GSPT1, impacting cancers driven by MYC family transcription factors, with a focus on metastatic castrate-resistant prostate cancer (mCRPC).

• Preclinical data showed strong efficacy, especially in combination with androgen receptor antagonists.

• Upcoming data in the second half of the year will focus on safety and efficacy in heavily pretreated mCRPC patients, including genomic profiling.

• Early results suggest potential for combination strategies and genomics-driven patient selection.

VAV1 degrader and Novartis partnership

• VAV1 is a first-in-class target in autoimmune diseases, previously considered undruggable; the degrader showed >90% inhibition of cytokine release in ex vivo assays.

• Phase I healthy volunteer data demonstrated deep, sustained degradation and a favorable safety profile.

• The Novartis partnership enables broad exploration of indications, with an upfront payment of $150 million and plans for multiple phase II trials.

• Indications under consideration include IBD, rheumatoid arthritis, lupus, and Sjögren's syndrome, focusing on diseases driven by TH17 and B cells.